Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017.
BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening diseases and to improve the quality of life for patients with cancer and related diseases.
BioSight’s pipeline of targeted chemotherapy pro-drugs target cancer cells and release active chemotherapy drugs inside the cancer cells while significantly minimizing the toxicity associated with conventional chemotherapy treatments.
Astarabine™, the company’s lead proprietary product is in clinical stages for the treatment of leukemia.
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer